XLP IV Infusion contains Paracetamol 1% w/v as the active ingredient, formulated for intravenous administration to provide rapid analgesic and antipyretic effects. Paracetamol, a widely used non-opioid analgesic and antipyretic agent, acts centrally to inhibit prostaglandin synthesis, thereby reducing pain and fever. XLP IV Infusion is indicated for the management of mild to moderate pain, including postoperative pain, musculoskeletal pain, and headache, as well as for the reduction of fever when oral administration is not feasible or contraindicated. The intravenous route ensures prompt onset of action, making it suitable for patients requiring immediate symptom relief or those unable to tolerate oral medications. Dosage and administration should be carefully adjusted according to patient weight, clinical condition, and hepatic function to minimize the risk of hepatotoxicity associated with paracetamol overdose. Contraindications include hypersensitivity to paracetamol or any excipients. Caution is advised in patients with liver impairment, chronic alcohol use, or malnutrition. Adverse effects are generally rare but may include hypersensitivity reactions and, in overdose situations, severe hepatotoxicity. XLP IV Infusion should be administered under medical supervision with appropriate monitoring of liver function and overall patient status.